Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

K Henry; R J Wallace; P C Bellman; D Norris; R L Fisher; L L Ross; Q Liao; M S Shaefer; TARGET Study Team

doi:10.1086/318527

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

Identifier:nobleid.org/w1/20260515/3CCEC245

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3CCEC245.svg?ark=w1%2F20260515%2F3CCEC245)](https://nobleid.org/work/w1/20260515/3CCEC245)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

Identifier:nobleid.org/w1/20260515/3CCEC245

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3CCEC245.svg?ark=w1%2F20260515%2F3CCEC245)](https://nobleid.org/work/w1/20260515/3CCEC245)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work